Mergers & Acquisitions
By The Online Investor Staff, updated Wed., May. 13, 5:14 AM
Slide #64. Gyre Therapeutics, Inc. — Cullgen Inc.
| Acquirer: |
Gyre Therapeutics, Inc. (NASDAQ:GYRE) |
| Acquiree: |
Cullgen Inc. |
| Details: |
Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, today announced the closing of its acquisition of Cullgen Inc. (Cullgen), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader (TPD) and degrader antibody conjugate (DAC) therapies, in an all-stock transaction valued at approximately $300 million. |
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. Co. is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. Co. operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions.
Open the GYRE Page at The Online Investor »
Open the GYRE Page at The Online Investor (in a new window) »
